Selected Publications

1. Singh R, Peng S, Viswanath P, Shen L, Rao X, Fang B, Wang J, Sambandam V, Johnson FM. Noncanonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis. EMBO Molecular Medicine. 2019. In Press.

2. Sambandam V, Shen L, Tong P, Mazumdar T, Pickering C, Myers JN, Wang J, Frederick M, Johnson FM. PDK1 mediates NOTCH1-mutated head and neck squamous carcinoma vulnerability to therapeutic PI3K/mTOR inhibition. Clin Cancer Res. 2019. In press.

3.  Kalu N, Mazumdar T, Peng S, Tong P, Shen L, Wang J, Banerjee U, Myers JN, Pickering CR, Brunell D, Stephan CC and Johnson FM. Comprehensive Pharmacogenomic Profiling of Human Papillomavirus- Positive and -Negative Squamous Cell Carcinoma Identifies Sensitivity to Aurora Kinase inhibition in KMT2D Mutants. Cancer Letters, 2018, 431:64-72.

4. Kalu N, Mazumdar T, Peng S, Shen L, Sambandam V, Rao X, Xi Y, Li L, Qi Y, Gleber- Netto F, Patel A, Wang J, Frederick MJ, Myers JN, Pickering CR and Johnson FM. Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget, 2017. Sept 8(49): 86369-86383.

5. Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu NN, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Letters, 2017, 392:71-82

6.  Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget. e-Pub 6/2016. PMID: 27384992

7.   Ferrarotto R, Goonatilake R, Young Yoo S, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res. e-Pub 11/2015. PMID: 26597303.

8.  Peng S, Sen B, Mazumdar T, Byers LA, Diao L, Wang J, Tong P, Giri U, Heymach JV, Kadara HN, Johnson FM. Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. Oncotarget 7(1):565-79, 1/2016. e-Pub 11/2015. PMCID: PMC4808018.

9.  Mazumdar T, Sen B, Wang Y, Peng S, Nicholas C, Glisson BS, Myers JN, Johnson FM. Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers. Anticancer Drugs 26(8):835-42, 9/2015. e-Pub 6/2015. PMCID: PMC4515205

10.  Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM. A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. Mol Cancer Ther. e-Pub 9/2014. PMID: 25193510

11.  Peng S, Creighton CJ, Zhang Y, Sen B, Mazumdar T, Myers JN, Woolfson A, Lorenzi MV, Bell D, Williams MD, Johnson FM. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. Journal of Translational Medicine 11(1):198. e-Pub 8/2013

11.   Saintigny P, Peng S, Zhang L, Sen B, Wistuba II, Lippman SM, Girard L, Minna JD, Heymach JV, Johnson FM. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol Cancer Ther 11(9):2021-2032, 9/2012. e-Pub 7/2012. PMCID: PMC3438283.

12.  Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM. Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib. Sci Transl Med 4(136):136ra70, 5/2012. PMID: 22649091

13.   Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, Lai SY, Johnson FM. STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res 18(1):127-39, 1/2012. e-Pub 11/2011. PMCID: PMC3251692

14.   Sen B, Johnson FM. Regulation of SRC family kinases in human cancers. J Signal Transduct 2011:865819, 2011. e-Pub 4/2011. PMCID: PMC3135246

15.    Sen B, Peng S, Saigal B, Williams MD, Johnson FM. Distinct interactions between c-Src and C-Met in mediating resistance to c-Src inhibition in head and neck Cancer. Clin Cancer Res 17(3):514-24, 2/2011. e-Pub 11/2010. PMID: 21106725

16.   Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II Study of Dasatinib in Patients with Advanced Non-Small Cell Lung Cancer. J Clin Oncol 28(30):4609-4615, 10/2010. e-Pub 9/2010. PMCID: PMC2974341.

17.  Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches. Drug Resist Updat 13(3):67-78, 6/2010. e-Pub 5/2010. PMID: 20471303

18.  Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, Dong W, Bekele BN, Wistuba I, Johnson FM. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila) 2(12):1039-49, 12/2009. e-Pub 11/2009. PMID: 19934338

19.  Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 15(22):6852-61, 11/2009. e-Pub 10/2009. PMCID: PMC2935176

20.  Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM. Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-Small Cell Lung Cancer. Clin Cancer Res 15(13):4423-30, 7/2009. e-Pub 6/2009. PMID: 19531623.

21.  Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res 69(5):1958-65, 3/2009. e-Pub 2/2009. PMCID: PMC2929826

22.  Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src Kinase Inhibition results in Synergistic Antitumor Effects. Clin Cancer Res 13(14):4233-4244, 7/2007. PMID: 17634553

23.  Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11(19):6924-32, 11/2005. PMID: 16203784